Vascular, cardiac & structural
One of 5 mechanistic pathways to 🧬 Organ-specific bioregulation · 10 options
The tissues where age-related decline is most measurable — and where, if a tissue-specific signal did what the theory claims, you would expect to be able to detect it.
Vascular and cardiac endpoints are measurable, which makes this the easiest place to hold the bioregulator claims to account. Baseline first.
ApoB (Apolipoprotein B)Lipid Panel (Cholesterol, HDL, LDL, Triglycerides)hs-CRP (High-Sensitivity C-Reactive Protein)High-Sensitivity Troponin TVitamin D (25-Hydroxy)🫀 Real Cardiovascular Risk covers these in one panel →
What engages this pathway
Ordered by how directly each one acts on the mechanism above — never by how much trial evidence exists. Each links to its full breakdown with dosing, half-life and vendor.
💉 Cardiogen
Cardiac muscle bioregulator, proposed to restore age-declined gene expression in cardiomyocytes. Mechanistically the most metabolically demanding tissue to target, and untested outside the program.
💉 Chelohart
Oral cardiac peptide from the same series.
💉 Ventfort
Vascular wall bioregulator, proposed to support endothelial function.
💉 Vesugen
The synthetic vascular tripeptide (Lys-Glu-Asp).
💉 Cartalax
Cartilage bioregulator — the tissue with the least regenerative capacity, which makes it both the most interesting target and the hardest claim.
💉 Sigumir
Cartilage and bone bioregulator. If the tissue-specific theory holds anywhere it would matter most here, since cartilage has almost no regenerative capacity of its own.
💉 Gotratix
The skeletal-muscle peptide, which sits with cartilage and bone as the structural set. Proposed for age-related muscle loss by the same tissue-specificity argument. The theory would place it alongside resistance training and protein rather than in place of either, and no human trial has compared it with either.
💉 Koramin
The heart CYTAMIN — the older organ-extract line, 155mg per tablet against Chelohart's capsule and Cardiogen's synthetic peptide. Search its name on PubMed and you get exactly one record, from 1947, about treating asthma with nikethamide: a name collision, not a citation. Heart is one of the few organs where the tissue-specificity claim was actually tested, and that test used synthetic peptides on rat explants in a dish.
💉 Vasalamin
The vessel CYTAMIN, and the most expensive tablet in the line at $53. Its own school's transport papers argue these peptides need the PEPT and LAT carriers to cross a membrane — carriers built for di- and tripeptides, which have no tissue of origin. That is the class premise arguing against itself. Blood pressure, ApoB, Lp(a) and hs-CRP together cost less than one pack, and none has ever been reported for it.
💉 Hondramin
The cartilage CYTAMIN. Cartilage is avascular — chondrocytes are fed by diffusion from synovial fluid through dense matrix — so this is the one product in the line facing a second barrier after the gut, and neither has been measured. The school's modern cartilage work is about defined peptides pushing stem cells toward a chondrogenic fate, which predicts the largest effect in growth and repair and the smallest in the aging joint people buy it for.
What actually decides this outcome, in order of size
This is the one bioregulator page whose claimed target has cheap, validated human read-outs already sitting in the marker estate. That changes what the page owes the reader. Ranked by how much of the outcome each one owns:
- Conventional vascular risk, which owns almost all of the variance and none of the romance. Blood pressure, apolipoprotein B, lipoprotein(a), smoking status and glycemia between them explain most of what happens to an artery over a decade. Nothing in the peptide series has been measured against any of them, in anyone.
- What the underlying research actually is, stated precisely. The series rests on tissue-specific peptide effects Khavinson 2001, effects on cell differentiation during aging Khavinson 2012, and a systematic review of peptide regulation of gene expression Khavinson 2021. Vascular endothelial cells specifically have been studied from the epigenetic angle Khavinson 2014. That is cell and tissue-culture work, and it is real work.
- The gap between that and a vascular outcome, which is the whole page. Between a peptide altering gene expression in cultured endothelium Khavinson 2014 and an artery behaving differently in a person there are four unmeasured steps: absorption, distribution to the vessel wall, a change in endothelial function, and a change in an outcome. No published human study on this series addresses any of them.
- That the missing measurement is available and inexpensive. This is the sentence that separates this page from its siblings. Endothelial biology has orderable surrogates, and a trial with a before-and-after design could have been run at any point in the last twenty years. It has not been, and the reason is not that the test is hard.
- The cardiac work, last, and its species. Cardiogen has been studied against myocardial tissue development in culture Chalisova 2009 and in a tumor model in senescent animals Levdik 2009. Both are legitimate experiments and neither is a human cardiovascular result.
The order to run these in, and what has to be true first
Establish the conventional risk picture, then treat anything here as an experiment you are running on yourself with a before and an after. Doing the second without the first is spending on the smallest term in the equation.
- The conventional panel first, because it is what will actually change your risk. ApoB (Apolipoprotein B) rather than LDL cholesterol, Lipoprotein(a) — Lp(a) once in a lifetime, Lipid Panel (Cholesterol, HDL, LDL, Triglycerides), HbA1c (Hemoglobin A1c) and hs-CRP (High-Sensitivity C-Reactive Protein). If any of these is abnormal, the highest-value action available from this hub is to leave it for ApoB & LDL particle reduction.
- Then draw the endothelial markers, before anything is taken. ADMA & SDMA is an endogenous inhibitor of nitric oxide synthase and is the closest orderable proxy for the function this page claims to support. Lp-PLA2 Activity and Myeloperoxidase (MPO) describe plaque inflammation. Homocysteine and Fibrinogen Activity complete a cheap vascular picture.
- Ventfort and Vesugen are the two with the most direct vascular claim. The peptide-regulation literature that supports them is gene-expression work Khavinson 2021 Khavinson 2014, and neuroprotective effects of related tripeptides have been described in mice Khavinson 2021. Read them as a hypothesis with a mechanism, not as a treatment with a result.
- Cardiogen and Chelohart are the cardiac pair and their evidence is animal and culture Chalisova 2009 Levdik 2009. If there is a diagnosed cardiomyopathy in the picture, the substrate arguments at Cardiac energetics & heart failure support have more behind them and belong first.
- Cartalax, Sigumir and Gotratix are cartilage, bone and muscle rather than vessel. Tissue specificity is the founding claim of the series Khavinson 2001 and it is also the reason these three do not belong in the same course as the vascular pair: if the theory is right, they are aimed elsewhere.
- Change one variable at a time, which on this page is unusually important. With no dose-response data, no pharmacokinetics and no human endpoint, a stack of five peptides produces an uninterpretable result whichever way it goes.
- Set the stopping rule before starting. Twelve weeks, one peptide, the same markers at the same laboratory. A reader who cannot say in advance what result would make them stop is not running an experiment.
What gets bought for this that cannot move it
The category fails on the same step every time: nobody has shown that an orally or subcutaneously administered short peptide reaches the tissue it is named after. Tissue specificity is the theory Khavinson 2001 and the demonstrations are in culture, where the peptide is applied directly to the cells Khavinson 2002. Applying a molecule to a dish is not a route of administration, and the missing step is pharmacokinetic rather than conceptual.
What makes this page different from its siblings is that the excuse does not apply. On the organ-peptide pages for liver, kidney and gut there is genuinely no simple assay for the claimed effect. Here there is: ADMA & SDMA, Lp-PLA2 Activity, Myeloperoxidase (MPO) and hs-CRP (High-Sensitivity C-Reactive Protein) are all orderable today, all cheap relative to a course, and all plausibly responsive to a real change in endothelial biology. Twenty years of mechanistic publication Khavinson 2021 without one before-and-after series in humans is a choice, and it is the strongest available evidence about how confident the field is.
Here is the extrapolation, labeled as one. IF a tetrapeptide did modulate endothelial gene expression in a living human the way it does in culture Khavinson 2014, THEN the first place it would be visible is a fall in ADMA & SDMA and in Lp-PLA2 Activity over one endothelial turnover, roughly two to three months, with no change in ApoB (Apolipoprotein B). That is a specific, cheap, falsifiable prediction. It is untested. It is not evidence, and nothing on this page should be bought as though it were.
If the goal is a vascular outcome, the honest routes are elsewhere. Particle count is ApoB & LDL particle reduction. Nitric oxide and vessel tone is Endothelial function & nitric oxide. Clotting and lipoprotein(a) is Thrombosis, Lp(a) & residual risk. Venous rather than arterial complaints are Venous & microcirculation. Every one of those has human endpoints behind it.
How you would know it was working, on a real read-out and a real timescale
This page makes the only prediction it is entitled to make, and it is a null. If the vascular peptides do nothing detectable, ADMA & SDMA and Lp-PLA2 Activity will be unchanged at twelve weeks. That is the expected result. Anybody who runs it properly and gets something else has produced the first human data this series has, which is a reason to record it carefully rather than to buy more.
- ADMA & SDMA at baseline and at 12 weeks, same laboratory, same fasting state. Asymmetric dimethylarginine competes with L-arginine at nitric oxide synthase, so it is mechanistically the right surrogate for an endothelial claim rather than a generic one. Twelve weeks is roughly one endothelial cell turnover, which is why an earlier repeat cannot show a structural effect.
- Lp-PLA2 Activity with Myeloperoxidase (MPO) on the same two draws. Both are enzymes released in vascular inflammation rather than general inflammation, which makes them harder to move by accident than hs-CRP (High-Sensitivity C-Reactive Protein) and therefore more informative if they do move.
- ApoB (Apolipoprotein B) and Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) as the negative control. No mechanism proposed for these peptides predicts a change in particle number. If apolipoprotein B moves, something else changed in the twelve weeks and the endothelial markers cannot be attributed.
- Comprehensive Metabolic Panel (CMP) and Complete Blood Count (CBC) with Differential before and after, because unlicensed injectables deserve safety monitoring even when the expected effect is nothing. Renal and hepatic function and a white cell count are the minimum for a compound with no human pharmacokinetic file.
- Blood pressure, twice daily, on a validated home monitor. It is the vascular read-out with the best outcome data attached, it is free after the device, and it is the one number on this page that would matter clinically if it changed.
What will fool you. ADMA rises with renal impairment and with acute illness and falls with improvements in diet and exercise, so a change over a winter is more likely to be about the winter. hs-CRP moves with any infection, including one you did not notice. People who start an expensive injectable also start walking, and the walking moves these markers Khavinson 2012 in the direction the peptide is being credited for. And a series with no published human dose-response Khavinson 2021 gives you no way to tell a null result from an under-dose, which is the specific reason a negative personal experiment here cannot close the question.
Sources read for these sections
- Khavinson VKh. Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging. Advances in Gerontology 2014 [Russian] · PMID 25051766
- Khavinson VK. Tissue-specific effects of peptides. Bulletin of Experimental Biology and Medicine 2001;132(2):807-808 · PMID 11713572
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
- Khavinson VKh. Peptides tissue-specifically stimulate cell differentiation during their aging. Bulletin of Experimental Biology and Medicine 2012 · PMID 22808515
- Chalisova NI, et al. The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats. Advances in Gerontology 2009 · PMID 20210190
- Levdik NV, et al. Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats. Bulletin of Experimental Biology and Medicine 2009 · PMID 20396706
- Khavinson VKh, Malinin VV, Chalisova NI, Grigor'ev EI. [Tissue-specific action of peptides in tissue culture of rats of various ages]. Advances in Gerontology 2002;9:95-100 [Russian] · PMID 12096446
- Khavinson V. Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer's Disease. Pharmaceuticals (Basel) 2021 · PMID 34071923
The other 4 routes to organ-specific bioregulation
Pick the pathway that matches where you are actually stuck. An appetite drug does nothing for someone who already undereats.
You know the goal. Skool has the plan.
This pathway is one arm of The Organ-specific bioregulation Blueprint. The members' version has where this arm sits in the sequence, what to stack it with, and the markers that tell you to keep going or stop.
Open The Organ-specific bioregulation Blueprint in Skool →$10/mo, cancel anytime.
← Open this pathway in the interactive Vault
Frequently asked questions
The tissues where age-related decline is most measurable — and where, if a tissue-specific signal did what the theory claims, you would expect to be able to detect it.
10 options are mapped to this pathway in the Vault, including Cardiogen, Chelohart, Ventfort, Vesugen. They are grouped by the mechanism they act through rather than ranked by how much trial evidence exists — 0 carry clinical validation and 10 are mechanistic predictions.
Vascular and cardiac endpoints are measurable, which makes this the easiest place to hold the bioregulator claims to account. Baseline first. The markers worth checking are ApoB (Apolipoprotein B), Lipid Panel (Cholesterol, HDL, LDL, Triglycerides), hs-CRP (High-Sensitivity C-Reactive Protein), High-Sensitivity Troponin T.
Unproven is not the same as ineffective. Of the 10 options on this pathway, 0 have clinical validation and 10 are graded theoretical — meaning the mechanism is sound but the specific human trial has not been run, which is true of a great deal of what works in this space. Nothing on this page is ordered by evidence tier, because sorting by trial count would bury the compounds you came looking for.
Where this goes next
Everything above is the free case for Vascular, cardiac & structural. The protocol — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.